Compare LIVE & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIVE | RNTX |
|---|---|---|
| Founded | 1968 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.3M | 35.5M |
| IPO Year | N/A | N/A |
| Metric | LIVE | RNTX |
|---|---|---|
| Price | $20.16 | $1.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 7.7K | ★ 208.9K |
| Earning Date | 02-05-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 4.93 | N/A |
| Revenue | ★ $444,944,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.09 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.25 | $1.02 |
| 52 Week High | $25.88 | $3.50 |
| Indicator | LIVE | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 66.72 | 43.52 |
| Support Level | $19.00 | $1.09 |
| Resistance Level | $21.00 | $1.25 |
| Average True Range (ATR) | 1.15 | 0.09 |
| MACD | 0.16 | 0.00 |
| Stochastic Oscillator | 84.05 | 53.57 |
Live Ventures Inc is a holding company for diversified businesses. It is focused on acquiring and operating profitable companies in various industries. The company operates in the business segments of Retail Entertainment which includes direct sales of entertainment and appliance products and services, Flooring Manufacturing, Steel Manufacturing, which includes the sale of steel plates, ground flat stock, and drill rods, and Corporate and Other. It derives key revenue from the Flooring Manufacturing segment which includes the manufacturing of carpets and rugs, yarn products, as well as a reseller of hard surface flooring products. Geographically the activities are carried out throughout the United States.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.